Back to Stocks

LUNG

Pulmonx Corp
7 filings tracked
healthcaremedical devicesSMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Pulmonx is demonstrating a clear path toward operational efficiency, highlighted by a significant surge in gross profit margins to 77.9%.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The narrative of margin expansion is countered by a shrinking top line and a precarious balance sheet. Revenue fell 8.7% year-over-year, exposing the company's vulnerability to single-market regulatory hurdles in China.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every LUNG filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The 10-Q paints a picture of a company at a crossroads, balancing impressive unit economics against a fragile capital structure. The increase in gross margin and the narrowing of net losses suggest that the core business model is viable, but the dependence on a single product line and the volatility of international regulatory approvals remain primary risks. The successful repayment of the CIBC loan and the transition to the Perceptive facility provide a temporary reprieve, but the high cost of this capital places a premium on immediate execution. Investors must weigh the potential of the AeriSeal System's regulatory approval against the reality of an accumulated deficit exceeding $535 million. The overall impact of the filing is neutral to slightly bullish on operational trends, but bearish on the financial risk profile. The next twelve months will be critical as the company seeks to prove that its growth can outpace its debt obligations and that the AeriSeal trial can deliver the necessary clinical results to justify its valuation.

Selected Quarter

Core Takeaway

The company is successfully improving unit economics and liquidity via a new loan, but remains vulnerable to regulatory delays in China and high debt servicing costs.

Investor Lens

The trade-off is between the potential for a massive market expansion via AeriSeal and the immediate risk of a debt-driven liquidity crisis.

Watch Next

China registration renewal status and CONVERT II trial data updates.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.03Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 4

Gross margins increased by 540 basis points to 77.9%.

margin expansion
70%
bearishMay 4

Revenue declined 8.7% YoY due to China registration pauses.

earnings miss
60%
neutralMay 4

Repaid CIBC loan and entered into a $60M senior secured facility with Perceptive.

debt restructure
50%
bullishMay 4

Gross margins increased by 540 basis points to 77.9%.

margin expansion
70%
bearishMay 4

Revenue declined 8.7% YoY due to China registration pauses.

earnings miss
60%
neutralMay 4

Repaid CIBC loan and entered into a $60M senior secured facility with Perceptive.

debt restructure
50%
bullishMay 4

Gross margins increased by 540 basis points to 77.9%.

margin expansion
70%
bearishMay 4

Revenue declined 8.7% YoY due to China registration pauses.

earnings miss
60%
neutralMay 4

Repaid CIBC loan and entered into a $60M senior secured facility with Perceptive.

debt restructure
50%
bullishMay 4

Gross margins increased by 540 basis points to 77.9%.

margin expansion
70%
bearishMay 4

Revenue declined 8.7% YoY due to China registration pauses.

earnings miss
60%
neutralMay 4

Repaid CIBC loan and entered into a $60M senior secured facility with Perceptive.

debt restructure
50%
bullishMay 4

Gross margins increased by 540 basis points to 77.9%.

margin expansion
70%
bearishMay 4

Revenue declined 8.7% YoY due to China registration pauses.

earnings miss
60%
neutralMay 4

Repaid CIBC loan and entered into a $60M senior secured facility with Perceptive.

debt restructure
50%
bullishMay 4

Gross margins increased by 540 basis points to 77.9%.

margin expansion
70%
bearishMay 4

Revenue declined 8.7% YoY due to China registration pauses.

earnings miss
60%
neutralMay 4

Repaid CIBC loan and entered into a $60M senior secured facility with Perceptive.

debt restructure
50%
bullishMay 4

Gross margins increased by 540 basis points to 77.9%.

margin expansion
70%
bearishMay 4

Revenue declined 8.7% YoY due to China registration pauses.

earnings miss
60%
neutralMay 4

Repaid CIBC loan and entered into a $60M senior secured facility with Perceptive.

debt restructure
50%

Filing History

10-QMay 4, 2026
Expand Sequence

The 10-Q paints a picture of a company at a crossroads, balancing impressive unit economics against a fragile capital structure. The increase in gross margin and the narrowing of net losses suggest that the core business model is viable, but the dependence on a single product line and the volatility of international regulatory approvals remain primary risks. The successful repayment of the CIBC loan and the transition to the Perceptive facility provide a temporary reprieve, but the high cost of this capital places a premium on immediate execution. Investors must weigh the potential of the AeriSeal System's regulatory approval against the reality of an accumulated deficit exceeding $535 million. The overall impact of the filing is neutral to slightly bullish on operational trends, but bearish on the financial risk profile. The next twelve months will be critical as the company seeks to prove that its growth can outpace its debt obligations and that the AeriSeal trial can deliver the necessary clinical results to justify its valuation.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.